Pharmaceutical News

RSS

NSF awards $3 million grant for establishing a Partnership in Research and Education in Materials

Professor Morris is principal investigator on a new, five-year $3 million National Science Foundation (NSF) grant that establishes a Partnership in Research and Education in Materials (PREM) at CCNY in collaboration with the University of Chicago's Materials Research Science and Engineering Center. The "overarching goal of the partnership is to develop methodology for description of material dynamics" as an emerging branch of materials science.

28 Oct 2009

Amgen to reduce price of Neulasta following Board's orders

The Board issued a Notice of Hearing on March 16, 2009, pertaining to allegations of Board Staff that Neulasta had been, and was being, sold by Amgen Canada Inc. at prices exceeding those indicated by the Board's Excessive Price Guidelines. On October 13, 2009, the Hearing Panel received a Joint Submission by Amgen and Board Staff along with a Voluntary Compliance Undertaking ("VCU") which proposed to resolve the issues raised in the Neulasta proceedings.

28 Oct 2009

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

InfoMedics, Inc., a company that engages patients and physicians to communicate better through the delivery of treatment feedback, has poster presentations at three industry conferences in October 2009. All of these studies provide a unique look at real-life patient feedback regarding experiences with medications for chronic conditions including ulcerative colitis (UC) and attention-deficit/hyperactivity disorder (ADHD) in adults and children.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

New clinical uses for old hypertension drug leads to several patents

University of South Florida neuroscientist R. Douglas Shytle's discovery of successful new clinical uses for mecamylamine, a drug once used to treat hypertension, has led to several issued patents on mecamylamine and related compounds. Earlier this month, Shytle, associate professor and research scientist at the USF Center of Excellence for Aging and Brain Repair and the USF Silver Child Development Center, received the university's 2009 "Excellence in Innovation" award.

28 Oct 2009

Folate-enriched prescription medical food lowers medical costs of patients with peripheral neuropathy

Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress.

28 Oct 2009

TOPROL-XL and metoprolol succinate are available for patients in all regions across the country: AstraZeneca

Following published reports that two generic companies had recalled or suspended shipments of metoprolol succinate, a beta-blocker medication taken by over half a million Americans for the treatment of high blood pressure, TOPROL-XL and its authorized generic, metoprolol succinate extended-release tablets are available.

28 Oct 2009

Shire receives European approval for FOSRENOL

Shire plc, the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL(R) (lanthanum carbonate), paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphorus level greather than or equal to 1.78mmol/L (5.5mg/dL).

28 Oct 2009

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Precision Antibody(TM) has been selected as the antibody developer for a component of the National Cancer Institute (NCI)'s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

28 Oct 2009

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology.

28 Oct 2009

Microbix and Hunan Biopharmaceutical to build $200-million influenza vaccine facility

Microbix, a developer of a patented technology that doubles the output of influenza vaccine production, announced today it has signed a joint venture agreement with the Hunan Biopharmaceutical Co. Ltd. (a Hunan Province state-owned enterprise) for initial financing to construct Asia's largest influenza vaccine production facility and the third largest vaccine plant in the world.

28 Oct 2009

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA.

28 Oct 2009

Recruitment of Phase II trial of TB-402 completed ahead of schedule

ThromboGenics NV and co-development partner BioInvent International announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule.

28 Oct 2009

POZEN announces Phase I study results of PA65020

POZEN Inc. announced today the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) and immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses (650 mg twice daily) of over-the-counter enteric-coated aspirin (EC-ASA) in healthy adults treated for one month.

28 Oct 2009

Mirafit fbcx reduces human body absorption of consumed fat

A scientific study to be presented today at the annual meeting of The Obesity Society will confirm significant weight loss using the pill mirafit fbcx®. Dr. K-L Catherine Jen and Dr. Joseph Artiss, principals at ArtJen Complexus USA, LLC, will present these clinical study findings today, October 27, at The Obesity Society 2009 annual scientific meeting at the Marriott Wardman Park Hotel in Washington, D.C., The Obesity Society's 27th annual scientific meeting.

28 Oct 2009

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.

28 Oct 2009

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NovaDel Pharma Inc., has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.

28 Oct 2009

King Pharmaceuticals receives exclusive rights to market and sell CYANOKIT

King Pharmaceuticals, Inc. announced today that it has licensed from Merck Santé S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany, the exclusive rights to market and sell CYANOKIT® 5 g (hydroxocobalamin for injection) ANTIDOTE in the U.S. CYANOKIT® is indicated for the treatment of known or suspected cyanide poisoning, typically caused by smoke inhalation from fires.

28 Oct 2009

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Prozac works wonders for some depressed people, but not for others. In some cases, patients derive little benefit and at worst, it can lead to bizarre hallucinations and fits of rage. Researchers and doctors remain puzzled as to what causes the wide range of reaction to Prozac and similar antidepressants.

28 Oct 2009

Medicines used for lowering blood cholesterol may be effective in the treatment of cancer

Millions of people around the world use medicines based on statins to lower their blood cholesterol, but new research from the University of Gothenburg, published in the prestigious journal PNAS, shows that statins may also be effective in the treatment of cancer.

27 Oct 2009

Pharmaceutical News

NSF awards $3 million grant for establishing a Partnership in Research and Education in Materials

Amgen to reduce price of Neulasta following Board's orders

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

New clinical uses for old hypertension drug leads to several patents

Folate-enriched prescription medical food lowers medical costs of patients with peripheral neuropathy

TOPROL-XL and metoprolol succinate are available for patients in all regions across the country: AstraZeneca

Shire receives European approval for FOSRENOL

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Microbix and Hunan Biopharmaceutical to build $200-million influenza vaccine facility

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Recruitment of Phase II trial of TB-402 completed ahead of schedule

POZEN announces Phase I study results of PA65020

Mirafit fbcx reduces human body absorption of consumed fat

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

King Pharmaceuticals receives exclusive rights to market and sell CYANOKIT

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Medicines used for lowering blood cholesterol may be effective in the treatment of cancer

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News